Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
08.10.2026 -
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
03.10.2026 -
Which S&P500 stocks are moving on Thursday?
01.10.2026 -
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
01.10.2026 -
Sanofi, Regeneron broaden alliance to find their next Dupixent
01.10.2026